Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
Karyopharm Therapeutics
Karyopharm Therapeutics is a Newton, Massachusetts-based commercial-stage pharmaceutical company developing and commercializing novel therapies for cancer and other diseases, with its lead asset XPOVIO (selinexor), an oral selective inhibitor of nuclear export (SINE) compound approved by the FDA for multiple oncology indications including multiple myeloma, endometrial cancer, and diffuse large B-cell lymphoma. The company is also advancing selinexor in myelofibrosis through its XPORT-MF-034 Phase 3 trial and exploring next-generation SINE compounds. In May 2026 stockholders approved an amendment to the 2022 Equity Incentive Plan (3.0M new shares added; Form 8-K May 21, 2026), and on July 13, 2026 the Board implemented a 2026 Leadership Cash & Equity Retention Program covering all named executive officers and the CFO using performance-based restricted stock units with a market-cap vesting hurdle (Form 8-K July 17, 2026, accession 0001193125-26-307964).
Company Info
Sector:Biotechnology / Oncology
Headquarters:Newton, Massachusetts, USA
Founded:2008
Website:www.karyopharm.com/
Upcoming Milestones & Key Dates
Q3 2026
Corporate
Q2 2026 financial results and XPOVIO commercial update
Clinical Development Pipeline
XPOVIO (selinexor)
Target: XPO1 (exportin 1) inhibitorSelinexor
Target: XPO1 inhibitorRecent News
It's crunch time for Karyopharm as company faces potential default next month
With its reserves depleted, a debt payment due in four weeks and its cash runway stretching only into next month, the question for Karyopharm Therapeutics is what’s next and how soon can it happen? | With its reserves depleted, a debt payment due in four weeks and its cash runway stretching only into next month, the question for Karyopharm Therapeutics is what’s next and how soon can it happen? The company sustained a $67 million loss in the second quarter, which is greater than its current cash
Karyopharm has a month left to salvage its cancer expansion plans
Karyopharm has a month left to salvage its cancer expansion plans
Leadership Team
Richard Paulson
President and Chief Executive Officer